Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Pelvic Cancer: early-phase trial registry

1 of 7 indexed Pelvic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Pelvic Cancer: 7 US clinical trials tracked, 1 recruiting.

Pelvic Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Varian, a Siemens Healthineers Company, running 2 of these trials.

Enrollment posture brief

Registry condition pelvic-cancer

OPEN 1 | RECR 14% | LATE 0 | EARLY 1 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%Pelvic Cancer (this)14%
Open-enrollment share among volume-matched conditions near Pelvic Cancer

Pelvic Cancer lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pelvic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pelvic Cancer is recruiting below its size-band peers.

    1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pelvic Cancer research.

    Varian, a Siemens Healthineers Company accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Pelvic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Pelvic Cancer research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Pelvic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pelvic Exercise Behavioral
1 trials
HyperSight imaging Device
1 trials
HyperSight Imaging Device
1 trials
Reirradiation Radiation
1 trials
Cardiopulmonary Exercise Testing (CPET) Other
1 trials
Observational Other
1 trials
Sunitinib Drug
1 trials
External Beam Radiation Therapy Radiation
1 trials

US sites by state

Facility locations filed on Pelvic Cancer trials. A trial with sites in several states counts in each.

Ohio 2 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Maryland 1 trials
Massachusetts 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pelvic Cancer page

7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pelvic Cancer condition card totals 7 registered trials; most-linked intervention Pelvic Exercise; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.